TP53 and hepatocellular carcinoma: Unfortunately, there is no commercially available HCC cell line with wild-type TP53. Clearly, there is a need to develop human HCC cell lines with wild-type TP53, and these cell lines would be critical to validate the specificity of trametinib against TP53 null HCC cells.